Header Logo

Connection

Kim Steegen to Lamivudine

Back to Details
This is a "connection" page, showing publications Kim Steegen has written about Lamivudine.
Kim Steegen
Connection Strength
0,196
Lamivudine
  1. Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment. Pediatr Infect Dis J. 2022 10 01; 41(10):827-834.
    View in: PubMed
    Score: 0,196
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.